45 / 154
A B S T R A C T S
S15
Prehabilitation in oncological surgery is evolving, particu-
larly in the field of colorectal cancer. The lecture will give a
presentation of the literature on this topic.
Disclosure of interest:
None declared
S46
STEREOTACTIC AND OTHER PROMISING ADVANCED
RADIATION TECHNIQUES IN ELDERLY
Cécile Ortholan
Department of Radiation Oncology, CHPG, Monaco
Radiation therapy in elderly patients has some particu-
larities: radiation oncologist often have to adapt the treatment
schedule to minimize the toxicity and to decrease the number
of sessions.
Stereotactic radiotherapy is a technic of radiation therapy
that uses focused radiation beam, to deliver high dose in a
small volume, in 1 to 5 sessions. Toxicity of such a treatment
is law in trained team. In elderly patients, stereotactic
radiation therapy could be indicated in small localized tumors
to replace surgery, or in oligometastatic disease to replace
systemic treatment.
For elderly patients with larger tumor or tumor requiring
prophylactic irradiation, hypofractionated schedule could be
an option. These schedules of radiotherapy deliver higher
dose per fraction, in a shorter amount of time than traditional
treatments. High conformational technique should be used to
minimize immediate and delayed toxicity.
To date, few prospective data are available to evaluate all
these techniques in elderly patients. Some randomized trials
are ongoing.
Disclosure of interest:
None declared
S47
PROSTATE CANCER
Heather Payne
University College Hospital, London, Oncology, London, UK
Prostate cancer is the most commonly occurring cancer
and the second leading cause of cancer-related death in men
in the European Union (EU) and the United States of America
(USA). It has been estimated that around 1 man in 7 will be
diagnosed with prostate cancer during his lifetime.
Prostate cancer is a disease that increases with age and is
commonly seen in older men. It is currently estimated that
over 65% of cases are diagnosed in men over the age of 65 and
the average age at presentation is 70 years. The number of
men living with all stages of prostate cancer will increase in
the coming decades as men continue to live longer.
The treatment opportunities for all men with prostate
cancer should be decided by their health status and personal
choices but not by chronological age.
It is important to assess the older men carefully and
especially to identify the ‘vulnerable’ men who with geriatric
intervention are likely to be able to be offered standard
therapy. The G-8 Geriatric Screening Tool is an efficient and
excellent way to assess those men who may benefit from
comprehensive geriatric evaluation.
In this session, I would like to concentrate on the challenges
of treating men who present with or progress to advanced
prostate cancer. We will consider the current therapy options
of hormonal therapy and chemotherapy and the results for
older men treated with these drugs in clinical trials and the
special considerations we needed for us to successfully use
these compounds in our everyday clinics
Disclosure of interest:
Heather Payne has attended and
received honoraria for advisory boards, travel expenses to
medical meetings and served as a consultant for AstraZeneca,
Astellas, Janssen, Sanofi Aventis, Takeda, Amgen, Ipsen,
Ferring, Sandoz, Roche and Novartis
S48
TREATMENT OF ELDERLY PATIENTS WITH AML
Rebecca Olin
University of California San Francisco, Department of Medicine,
San Francisco, USA
Clinical outcomes for older adults with AML have histori-
cally been dismal. Determination of fitness for induction
chemotherapy, and in parallel fitness for stem cell transplan-
tation, represents the crucial first step in treatment planning.
This presentation will discuss emerging data regarding the
utility of geriatric assessment in this setting. It will also
address recent data on novel therapeutic approaches which
have potential to change standard of care in this population.
Disclosure of interest:
None declared
S49
Raul Cordoba
The speaker abstract has not been received at the time of
publication.
S50
MASCC GUIDELINES IN FATIGUE ADAPTED TO GERIATRIC
ONCOLOGY
Fausto Roila
Medical Oncology Division, Department of Oncology, Terni, Italy
Cancer-related fatigue is one of the most common and
debilitating symptoms experienced by elderly cancer patients.